SUZHOU, China, March 17, 2026 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the first patient has been successfully dosed in the phase I clinical study (study code: JSKN027-101) of JSKN027, an independently developed innovative bispecific antibody-drug conjugate (ADC) targeting PD-L1 and VEGFR2, for the treatment of advanced malignant solid tumors. JSKN027 is the company's fifth ADC candidate entering clinical development, as well as the world's first PD-L1/ VEGFR2 bispecific ADC to advance into clinical trials.

As the global burden of malignant tumors continues to rise, there is an urgent clinical need for more effective and innovative therapies applicable across various tumor types. PD-L1 is a key molecule in regulating immune responses, and VEGFR2 is a core signaling hub in tumor angiogenesis. Within the immunosuppressive microenvironment of various solid tumors, the VEGF/VEGFR signaling pathway and the PD-1/PD-L1 axis exhibit a synergistic interplay, collectively driving immune evasion and providing a new strategy for dual-target therapy. JSKN027 is an innovative bispecific ADC designed based on this synergistic mechanism. By leveraging glycan-specific conjugation technology, it precisely links its cleavable linker and topoisomerase I inhibitor payload to the antibody's Fc region. This design confers multiple mechanisms of action, including targeted chemotherapy, anti-angiogenesis and immunotherapy. It is expected to synergistically enhance antitumor efficacy and overcome therapeutic resistance, offering a promising treatment strategy across solid tumors.

JSKN027-101 is an open-label, multi-center, Phase I clinical study, including dose-escalation and dose-expansion phases. This study aims to evaluate the safety, tolerability, pharmacokinetics (PK)/pharmacodynamics (PD), and antitumor activity of JSKN027 in patients with advanced malignant solid tumors, and determine the maximum tolerated dose (MTD) and/or recommended Phase II dose (RP2D).

About JSKN027

JSKN027 is a first-in-class bispecific ADC designed to co-engage PD-L1 and VEGFR2. By leveraging glycan-specific conjugation technology, it precisely links its cleavable linker and topoisomerase I inhibitor payload to the antibody's Fc region – maintaining a strong safety profile while unlocking potent anti-tumor activity.

JSKN027's efficacy stems from a unique three-fold synergistic mechanism. Beyond the standard ADC effects of targeted cell killing and bystander activity, it also inhibits tumor angiogenesis by blocking VEGF/VEGFR2 signaling and reverses immune suppression by disrupting the PD-1/PD-L1 checkpoint. This integrated attack enhances overall anti-tumor power and is anticipated to help overcome therapeutic resistance. As a result, JSKN027 is poised to offer a novel and robust treatment avenue for patients across multiple solid tumor types. The Phase I clinical study of JSKN027 in patients with advanced malignant solid tumors has been conducted in China.

About Alphamab Oncology

Alphamab Oncology (Stock Code: 9966.HK) is an innovative biopharmaceutical company focused on oncology. Leveraging proprietary platforms including single-domain antibodies, bispecific antibodies, glycan-specific conjugation, linker-payloads, dual-payload ADCs, and high-concentration subcutaneous formulations, the Company has built a differentiated and globally competitive pipeline, covering cutting-edge candidates in ADCs, bispecific antibodies, and single-domain antibodies.

One product has received market approval: Envafolimab (KN035, brand name: 恩维达^®), the world's first subcutaneously injected PD-(L)1 inhibitor, offering greater convenience and accessibility in cancer treatment. The NMPA has accepted the new drug application for KN026 (Anbenitamab Injection), a HER2 bispecific antibody, for second-line or later HER2-positive gastric cancer. Five bispecific ADC candidates have entered clinical stages, and next-generation ADC pipelines—such as dual-payload ADCs—are advancing rapidly. The Company has established strategic partnerships with organizations including CSPC, ArriVent, and Glenmark, covering both product development and technology platforms.

Our overarching mission is to make cancer manageable and curable by addressing unmet clinical needs in oncology. Alphamab Oncology is continuously dedicated to the development of effective, safe, and globally competitive anti-tumor drugs, enabling patients to achieve long-term, high-quality survival and delivering China-innovated cancer therapies to benefit patients worldwide.

Source: Alphamab Oncology Related Stocks: HongKong:9966